915360-45-1

Upstream product

• 214485-08-2 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-quinoline-3-carbonitrile 
• 1709-44-0 m-aminobenzaldehyde 
• 214485-09-3 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-quinoline-3-carbonitrile 
• 214470-37-8 4-chloro-6-nitro-3-quinolinecarbonitrile 
• 2305-65-9 4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 100-01-6 4-nitro-aniline 
• 57338-20-2 2-Cyano-3-(4-nitro-phenylamino)-acrylic acid ethyl ester 

Relevant academic research and scientific papers

3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same

The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, m and n are defined as

Inhibition of Tpl2 kinase and TNFα production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis

The synthesis and structure-activity studies of a series of quinoline-3-carbonitriles as inhibitors of Tpl2 kinase are described. Potent inhibitors of Tpl2 kinase with selectivity against a panel of selected kinases in enzymatic assays and specificity in cell-based phosphorylation assays in LPS-treated human monocytes were identified. Selected inhibitors with moderate activity in human whole blood assay effectively inhibited LPS/D-Gal induced TNFα release when administered intraperitoneally in mice.